Aquestive Therapeutics (AQST) CCO has RSU shares withheld for taxes

Rhea-AI Filing Summary

Aquestive Therapeutics, Inc. reported a routine insider tax event involving its Chief Commercial Officer, Sherry Korczynski. On this Form 4, the company withheld 2,714 shares of common stock to cover her tax withholding obligation tied to the vesting of previously granted RSUs.

These shares were not sold on the open market; they were retained by the issuer to satisfy taxes. After this withholding, Korczynski directly holds 238,403 shares of Aquestive Therapeutics common stock, reflecting her ongoing equity stake following the RSU vesting.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Korczynski Sherry

Role Chief Commercial Officer

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	2,714	$0.00	--

Holdings After Transaction: Common Stock — 238,403 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares withheld for taxes: 2,714 shares Shares held after transaction: 238,403 shares

2 metrics

Shares withheld for taxes 2,714 shares Tax withholding on vesting RSUs, transaction dated 2026-06-08

Shares held after transaction 238,403 shares Directly held common stock following tax-withholding disposition

Key Terms

Restricted Stock Units ("RSUs"), tax withholding obligation, tax-withholding disposition

3 terms

Restricted Stock Units ("RSUs") financial

"in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted"

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

tax withholding obligation financial

"to satisfy the Reporting Person's tax withholding obligation in connection with the vesting"

tax-withholding disposition financial

"transaction_action": "tax-withholding disposition""

A tax-withholding disposition is an event or transaction—such as selling or transferring securities, exercising options, or receiving compensation—that triggers a requirement to hold back part of the payment and remit it to tax authorities. It matters to investors because it reduces the cash they receive immediately and can change the timing and amount of taxable income, like a cashier taking a portion of your sale proceeds to pay taxes before you get the rest.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Korczynski Sherry

(Last) (First) (Middle)

C/O AQUESTIVE THERAPEUTICS, INC.

30 TECHNOLOGY DRIVE

(Street)

WARREN NEW JERSEY 07059

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Aquestive Therapeutics, Inc. [ AQST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/08/2026		F		2,714(1)	D	$0	238,403	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person.

Remarks:

	/s/ Thomas Zalewski, as Attorney-In-Fact	06/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did AQST report for Sherry Korczynski?

Aquestive Therapeutics reported that Chief Commercial Officer Sherry Korczynski had 2,714 shares of common stock withheld to cover taxes on vesting RSUs. This was a compensation-related tax event rather than an open-market stock purchase or sale.

How many AQST shares were withheld for taxes in this Form 4?

The filing shows 2,714 Aquestive Therapeutics common shares were withheld by the company to satisfy Sherry Korczynski’s tax obligation. This withholding occurred in connection with the vesting of previously granted Restricted Stock Units, a standard mechanism for equity compensation taxes.

Did the AQST Chief Commercial Officer sell shares on the open market?

No open-market sale is reported. The Form 4 describes a tax-withholding disposition where 2,714 shares were withheld by the issuer for taxes on vesting RSUs. This type of transaction does not involve selling shares into the market for cash proceeds.

How many AQST shares does Sherry Korczynski hold after this transaction?

After the tax-withholding event, Sherry Korczynski directly holds 238,403 shares of Aquestive Therapeutics common stock. This figure reflects her remaining equity position following the RSU vesting and the company’s withholding of 2,714 shares to pay related tax obligations.

What triggered the AQST tax-withholding disposition reported on Form 4?

The disposition was triggered by the vesting of certain Restricted Stock Units previously granted to Sherry Korczynski. To meet her tax withholding obligation arising from that vesting, Aquestive Therapeutics withheld 2,714 shares of common stock instead of requiring a separate cash payment.